323 related articles for article (PubMed ID: 21416169)
1. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
Cysique LA; Brew BJ
J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
[TBL] [Abstract][Full Text] [Related]
2. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
[TBL] [Abstract][Full Text] [Related]
5. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Bunupuradah T; Chetchotisakd P; Jirajariyavej S; Valcour V; Bowonwattanuwong C; Munsakul W; Klinbuayaem V; Prasithsirikul W; Sophonphan J; Mahanontharit A; Hirschel B; Bhakeecheep S; Ruxrungtham K; Ananworanich J;
J Neurovirol; 2012 Dec; 18(6):479-87. PubMed ID: 22993101
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
[TBL] [Abstract][Full Text] [Related]
9. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.
Childers ME; Woods SP; Letendre S; McCutchan JA; Rosario D; Grant I; Mindt MR; Ellis RJ;
J Neurovirol; 2008 Nov; 14(6):550-7. PubMed ID: 19016380
[TBL] [Abstract][Full Text] [Related]
10. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Muñoz-Moreno JA; Fumaz CR; Prats A; Ferrer MJ; Negredo E; Pérez-Alvarez N; Moltó J; Gómez G; Garolera M; Clotet B
J Neurovirol; 2010 May; 16(3):208-18. PubMed ID: 20450380
[TBL] [Abstract][Full Text] [Related]
11. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.
Marcotte TD; Deutsch R; McCutchan JA; Moore DJ; Letendre S; Ellis RJ; Wallace MR; Heaton RK; Grant I;
Arch Neurol; 2003 Oct; 60(10):1406-12. PubMed ID: 14568811
[TBL] [Abstract][Full Text] [Related]
12. Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.
Gras L; de Wolf F; Smit C; Prins M; van der Meer JT; Vanhommerig JW; Zwinderman AH; Schinkel J; Geskus RB;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):536-42. PubMed ID: 25559595
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic network connectivity abnormalities in HIV-infected individuals over age 60.
Guha A; Wang L; Tanenbaum A; Esmaeili-Firidouni P; Wendelken LA; Busovaca E; Clifford K; Desai A; Ances BM; Valcour V
J Neurovirol; 2016 Feb; 22(1):80-7. PubMed ID: 26265137
[TBL] [Abstract][Full Text] [Related]
15. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
[TBL] [Abstract][Full Text] [Related]
16. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive symptoms and impairment in an HIV community clinic.
Kim DH; Jewison DL; Milner GR; Rourke SB; Gill MJ; Power C
Can J Neurol Sci; 2001 Aug; 28(3):228-31. PubMed ID: 11513341
[TBL] [Abstract][Full Text] [Related]
20. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
